RankAlpha logo
Back to Rankings

ADMA

ADMA BiologicsD
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-03
View Chart
Current thesis
The constructive read is that Q1 exposed a temporary channel and pricing reset rather than a demand break: ASCENIV grew 28% year over year, gross margin reached 71%, and operating cash flow was $58 million, while management said April demand tracked first-quarter direct sales and called Q1 a likely trough baseline [#8-K-2026-05-06].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +9.0.
What can break
ADMA remains highly dependent on ASCENIV staying insulated from broader IG pricing pressure; if ASCENIV demand or pricing weakens, the trough-recovery thesis breaks.
Momentum
3
Value
65
Sentiment
68
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $8.90 · Bull $12.50 · Bear $6.50
Data freshness
Prices
As of 2026-06-03
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-03 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-03
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $30.00
Why
Momentum3 · Δ7d +0.0
Value65 · Δ7d +0.6
Sentiment68 · Δ7d +9.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
3
34% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
+0.2
Value
65
32% active weight
Current posture
7d trendFlat
Δ7d
+0.6
Δ21d
+1.2
Sentiment
68
33% active weight
Current posture
7d trendImproving
Δ7d
+9.0
Δ21d
+19.3
Why this grade

Composite grade D. Momentum 2.9 / Value 65.3 / Sentiment 67.8

Fundamentals (TTM)
As of 2026-06-02
Market Cap
$1.76B
Beta
0.49
Shares Out
238M
P/E (TTM)
21.3
P/S (TTM)
8.78
P/FCF (TTM)
105.67
Rev YoY
+12.0%
EPS YoY
+1.5%
Gross Margin
+54.7%
Op Margin
+33.2%
Net Debt
-$30.81M
Current Ratio
7.13
As of 2026-06-03 • Updated nightlySource: Internal modelMethodology